Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2a,Condition 2b,Condition 2c,Condition 3a,Condition 3b
102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",erythrocyte quantity,,RS:0000363,F344/NHsd,male,105 days,12,,CMO:0000037,hematocrit,,,median,46,%,,,MMO:0000214,hematocrit analysis,,0,,,,,control condition,66131,control condition,,,,,,
102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",erythrocyte quantity,,RS:0000363,F344/NHsd,male,105 days,23,,CMO:0000037,hematocrit,,,median,70,%,,,MMO:0000214,hematocrit analysis,,0,,,,,air oxygen content (10 %) (for 21 days),66132,air oxygen content (10 %) (for 21 days),,,,,,
102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",erythrocyte quantity,,RS:0001072,WKY/NCruk,male,105 days,12,,CMO:0000037,hematocrit,,,median,45,%,,,MMO:0000214,hematocrit analysis,,0,,,,,control condition,66133,control condition,,,,,,
102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",erythrocyte quantity,,RS:0001072,WKY/NCruk,male,105 days,28,,CMO:0000037,hematocrit,,,median,71,%,,,MMO:0000214,hematocrit analysis,,0,,,,,air oxygen content (10 %) (for 21 days),66134,air oxygen content (10 %) (for 21 days),,,,,,
151,"Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57.",erythrocyte quantity,,RS:0000145,BN/NHsdMcwi,female,92 days to 89 days,15,,CMO:0000037,hematocrit,,,,41.6,%,0.4,1.5492,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days),69481,controlled sodium content diet (0.4 %) (for 35 days),,controlled sodium content diet (0.1 %) (for 35 days),,,controlled sodium content diet (8 %) (between 22 and 24 days),
151,"Moreno C, et al., Physiol Genomics 2003 Nov 11;15(3):243-57.",erythrocyte quantity,,RS:0000811,SS/JrHsdMcwi,female,92 days to 89 days,15,,CMO:0000037,hematocrit,,,,38.8,%,1.4,5.4222,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium content diet (0.4 %) (for 35 days) then controlled sodium content diet (0.1 %) (for 35 days) then controlled sodium content diet (8 %) (between 22 and 24 days),69482,controlled sodium content diet (0.4 %) (for 35 days),,controlled sodium content diet (0.1 %) (for 35 days),,,controlled sodium content diet (8 %) (between 22 and 24 days),
567,"Yao H, et al., Physiol Genomics. 2007 Feb 27;.",erythrocyte quantity,,RS:0000770,SHRSP/Izm,male,84 days to 70 days,8,,CMO:0000037,hematocrit,,,,42,%,0.7071,2.0,MMO:0000214,hematocrit analysis,,0,,,,,control condition,65523,control condition,,,,,,
567,"Yao H, et al., Physiol Genomics. 2007 Feb 27;.",erythrocyte quantity,,RS:0000770,SHRSP/Izm,male,150 days,7,,CMO:0000037,hematocrit,,,,44,%,1.1339,3.0,MMO:0000214,hematocrit analysis,,0,,,,,control condition,65524,control condition,,,,,,
567,"Yao H, et al., Physiol Genomics. 2007 Feb 27;.",erythrocyte quantity,,RS:0001433,SHRSP.WKY-(D1Wox29-D1Arb21)/Izm,male,150 days,9,,CMO:0000037,hematocrit,,,,45,%,0.6667,2.0,MMO:0000214,hematocrit analysis,,0,,,,,control condition,65525,control condition,,,,,,
567,"Yao H, et al., Physiol Genomics. 2007 Feb 27;.",erythrocyte quantity,,RS:0001433,SHRSP.WKY-(D1Wox29-D1Arb21)/Izm,male,84 days to 70 days,7,,CMO:0000037,hematocrit,,,,43,%,0.378,1.0,MMO:0000214,hematocrit analysis,,0,,,,,control condition,65526,control condition,,,,,,
2561,"Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000.",erythrocyte quantity,,RS:0000592,MW,male,0 days,8,,CMO:0000037,hematocrit,,,,40,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,5/6 nephrectomy,28,days,nephrectomy (for 28 days) then control condition,100986,nephrectomy (for 28 days),,control condition,,,,
2561,"Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000.",erythrocyte quantity,,RS:0000592,MW,male,0 days,8,,CMO:0000037,hematocrit,,,,38,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,5/6 nephrectomy,28,days,nephrectomy (for 28 days) then enalapril (50 mg/l) (for 21 days),100987,nephrectomy (for 28 days),,enalapril (50 mg/l) (for 21 days),,,,
2561,"Anderson S, et al., J Clin Invest. 1986 Jun;77(6):1993-2000.",erythrocyte quantity,,RS:0000592,MW,male,0 days,8,,CMO:0000037,hematocrit,,,,36,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,5/6 nephrectomy,28,days,nephrectomy (for 28 days) then reserpine (5 mg/l) (for 21 days) and hydralazine (80 mg/l) (for 21 days) and controlled hydralazine content drinking water (25 mg/l) (for 21 days),100988,nephrectomy (for 28 days),,reserpine (5 mg/l) (for 21 days),hydralazine (80 mg/l) (for 21 days),controlled hydralazine content drinking water (25 mg/l) (for 21 days),,
2801,"Huang BS, et al., Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H517-24. doi: 10.1152/ajpheart.00651.2004. Epub 2004 Sep 30.",erythrocyte quantity,,RS:0000785,SR/Hsd,male,56 days to 49 days,N/A,,CMO:0000037,hematocrit,,-,,38,%,2.0,,MMO:0000214,hematocrit analysis,,0.0,,,,,artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days),103230,artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days),,,,,,
2801,"Huang BS, et al., Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H517-24. doi: 10.1152/ajpheart.00651.2004. Epub 2004 Sep 30.",erythrocyte quantity,,RS:0000785,SR/Hsd,male,56 days to 49 days,N/A,,CMO:0000037,hematocrit,,-,,39,%,2.0,,MMO:0000214,hematocrit analysis,,0.0,,,,,aldosterone (22.5 ng/hr) (for 14 days) and artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days),103231,aldosterone (22.5 ng/hr) (for 14 days),artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days),,,,,
2801,"Huang BS, et al., Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H517-24. doi: 10.1152/ajpheart.00651.2004. Epub 2004 Sep 30.",erythrocyte quantity,,RS:0000922,SS/Hsd,male,56 days to 49 days,N/A,,CMO:0000037,hematocrit,,-,,41,%,2.0,,MMO:0000214,hematocrit analysis,,0.0,,,,,artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days),103232,artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days),,,,,,
2801,"Huang BS, et al., Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H517-24. doi: 10.1152/ajpheart.00651.2004. Epub 2004 Sep 30.",erythrocyte quantity,,RS:0000922,SS/Hsd,male,56 days to 49 days,N/A,,CMO:0000037,hematocrit,,-,,40,%,3.0,,MMO:0000214,hematocrit analysis,,0.0,,,,,aldosterone (22.5 ng/hr) (for 14 days) and artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days),103233,aldosterone (22.5 ng/hr) (for 14 days),artificial cerebrospinal fluid with 0.15 M sodium (4.4-4.6 ul/hr) (for 14 days),,,,,
2582,"Jung FF, etal., J Am Soc Nephrol. 1995 Feb;5(8):1573-80.",erythrocyte quantity,,RS:0000681,SD,male,90 days,9,,CMO:0000037,hematocrit,,,,46,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,101220,control condition,,,,,,
2582,"Jung FF, etal., J Am Soc Nephrol. 1995 Feb;5(8):1573-80.",erythrocyte quantity,,RS:0000681,SD,male,450 days to 420 days,9,,CMO:0000037,hematocrit,,,,45,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,101221,control condition,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,41,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100436,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,7,,CMO:0000037,hematocrit,,,,39,%,1.0,2.6458,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,23,days,puromycin aminonucleoside (50 mg/kg) ,100437,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,5,,CMO:0000037,hematocrit,,,,35,%,1.0,2.2361,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,23,days,controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) ,100438,controlled enalapril content drinking water (50 mg/l) (for 30 days),,puromycin aminonucleoside (50 mg/kg) ,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,45,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100439,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,43,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100440,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,43,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100441,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),,puromycin aminonucleoside (50 mg/kg) ,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,44,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100442,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,44,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100443,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,42,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100444,controlled enalapril content drinking water (50 mg/l) (for 497 days),,puromycin aminonucleoside (50 mg/kg) ,,,,
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",erythrocyte quantity,,RS:0003240,MWF/ZtmRrrc,male,126 days,8,,CMO:0000037,hematocrit,,,,50,%,0.3536,1.0,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,100913,control condition,,,,,,
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",erythrocyte quantity,,RS:0003240,MWF/ZtmRrrc,male,126 days,10,,CMO:0000037,hematocrit,,,,51,%,0.3162,1.0,MMO:0000214,hematocrit analysis,,0.0,,,,,enalapril (50 mg/l) (for 60 days),100914,enalapril (50 mg/l) (for 60 days),,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,11,,CMO:0000037,hematocrit,,,,45.2,%,1.4,4.6433,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99975,unilateral nephrectomy (for 28 days),,vehicle control condition,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,17,,CMO:0000037,hematocrit,,,,44.8,%,0.6,2.4739,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99976,unilateral nephrectomy (for 28 days),,streptozotocin (35 mg/kg) ,,,vehicle control condition,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,17,,CMO:0000037,hematocrit,,,,45.6,%,0.3,1.2369,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days),99977,unilateral nephrectomy (for 28 days),,streptozotocin (35 mg/kg) ,,,bosentan (100 mg/kg/d) (for 154 days),
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,16,,CMO:0000037,hematocrit,,,,45.8,%,0.5,2.0,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),99978,unilateral nephrectomy (for 28 days),,streptozotocin (35 mg/kg) ,,,enalapril (10 mg/kg/d) (for 154 days),
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,16,,CMO:0000037,hematocrit,,,,44.5,%,0.6,2.4,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),99979,unilateral nephrectomy (for 28 days),,streptozotocin (35 mg/kg) ,,,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days)
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,9,,CMO:0000037,hematocrit,,,,47.3,%,0.9,2.7,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then enalapril (20 mg/kg/d) ,100851,right nephrectomy (for 56 days),,enalapril (20 mg/kg/d) ,,,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,44,%,1.0,3.1623,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then lisinopril (10 mg/kg/d) ,100852,right nephrectomy (for 56 days),,lisinopril (10 mg/kg/d) ,,,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,7,,CMO:0000037,hematocrit,,,,44.5,%,2.4,6.3498,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then angiotensin II receptor antagonist (20 mg/l) ,100853,right nephrectomy (for 56 days),,angiotensin II receptor antagonist (20 mg/l) ,,,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,5,,CMO:0000037,hematocrit,,,,45,%,1.1,2.4597,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then angiotensin II receptor antagonist (80 mg/l) ,100854,right nephrectomy (for 56 days),,angiotensin II receptor antagonist (80 mg/l) ,,,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,6,,CMO:0000037,hematocrit,,,,41.2,%,1.7,4.1641,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days),100855,right nephrectomy (for 112 days),,,,,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,45.8,%,0.7,2.2136,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then reserpine (5 mg/l) (for 56 days) and hydralazine (80 mg/l) (for 56 days) and controlled hydralazine content drinking water (25 mg/l) (for 56 days),100856,right nephrectomy (for 112 days),,reserpine (5 mg/l) (for 56 days),hydralazine (80 mg/l) (for 56 days),controlled hydralazine content drinking water (25 mg/l) (for 56 days),,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,45.3,%,1.1,3.4785,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then captopril (30 mg/kg/d) (for 56 days),100857,right nephrectomy (for 112 days),,captopril (30 mg/kg/d) (for 56 days),,,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,9,,CMO:0000037,hematocrit,,,,44.6,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then enalapril (20 mg/kg/d) (for 56 days),100858,right nephrectomy (for 112 days),,enalapril (20 mg/kg/d) (for 56 days),,,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,44,%,1.0,3.1623,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then lisinopril (10 mg/kg/d) (for 56 days),100859,right nephrectomy (for 112 days),,lisinopril (10 mg/kg/d) (for 56 days),,,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,7,,CMO:0000037,hematocrit,,,,40.5,%,2.1,5.5561,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then angiotensin II receptor antagonist (20 mg/l) (for 56 days),100860,right nephrectomy (for 112 days),,angiotensin II receptor antagonist (20 mg/l) (for 56 days),,,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,5,,CMO:0000037,hematocrit,,,,41,%,1.9,4.2485,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,112,days,right nephrectomy (for 112 days) then angiotensin II receptor antagonist (80 mg/l) (for 56 days),100861,right nephrectomy (for 112 days),,angiotensin II receptor antagonist (80 mg/l) (for 56 days),,,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,6,,CMO:0000037,hematocrit,,,,44.8,%,0.6,1.4697,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days),100848,right nephrectomy (for 56 days),,,,,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,48.4,%,1.4,4.4272,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then reserpine (5 mg/l) and hydralazine (80 mg/l) and controlled hydralazine content drinking water (25 mg/l) ,100849,right nephrectomy (for 56 days),,reserpine (5 mg/l) ,hydralazine (80 mg/l) ,controlled hydralazine content drinking water (25 mg/l) ,,
2523,"Kakinuma Y, et al., Kidney Int. 1992 Jul;42(1):46-55.",erythrocyte quantity,,RS:0000592,MW,male,0 days,10,,CMO:0000037,hematocrit,,,,46.7,%,0.8,2.5298,MMO:0000214,hematocrit analysis,,0.0,,~5/6 to 7/8 nephrectomy,56,days,right nephrectomy (for 56 days) then captopril (30 mg/kg/d) ,100850,right nephrectomy (for 56 days),,captopril (30 mg/kg/d) ,,,,
2802,"Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.",erythrocyte quantity,,RS:0000786,SR/Jr,male,63 days,16,,CMO:0000037,hematocrit,,,,45.8,%,0.4,1.6,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium chloride content diet (0.3 %) (for 35 days),103266,controlled sodium chloride content diet (0.3 %) (for 35 days),,,,,,
2802,"Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.",erythrocyte quantity,,RS:0000786,SR/Jr,male,63 days,13,,CMO:0000037,hematocrit,,,,43.5,%,0.5,1.8028,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium chloride content diet (8 %) (for 35 days),103267,controlled sodium chloride content diet (8 %) (for 35 days),,,,,,
2802,"Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.",erythrocyte quantity,,RS:0000817,SS/Jr,male,63 days,15,,CMO:0000037,hematocrit,,,,48.8,%,0.5,1.9365,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium chloride content diet (0.3 %) (for 35 days),103268,controlled sodium chloride content diet (0.3 %) (for 35 days),,,,,,
2802,"Vokurkov? M, et al., Hypertens Res. 2003 May;26(5):397-404.",erythrocyte quantity,,RS:0000817,SS/Jr,male,63 days,10,,CMO:0000037,hematocrit,,,,47,%,2.2,6.957,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled sodium chloride content diet (8 %) (for 35 days),103269,controlled sodium chloride content diet (8 %) (for 35 days),,,,,,
3138,"Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206.",erythrocyte quantity,,RS:0004778,MWF/Ztm,female,147 days to 126 days,8,,CMO:0000037,hematocrit,,,,47.7,%,0.495,1.4,MMO:0000214,hematocrit analysis,,0.0,,,,,arterial catheter implantation and controlled hemorrhage,109206,arterial catheter implantation and controlled hemorrhage,,,,,,
3138,"Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206.",erythrocyte quantity,,RS:0004778,MWF/Ztm,male,147 days to 112 days,8,,CMO:0000037,hematocrit,,,,49.5,%,0.4243,1.2,MMO:0000214,hematocrit analysis,,0.0,,,,,arterial catheter implantation and controlled hemorrhage,109205,arterial catheter implantation and controlled hemorrhage,,,,,,
3163,"Fassi A, etal., Am J Kidney Dis. 1999 Feb;33(2):267-75. doi: 10.1016/s0272-6386(99)70299-4.",erythrocyte quantity,,RS:0000594,MWF,male,147 days to 133 days,7,,CMO:0000037,hematocrit,,,,45,%,1.1339,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,castor oil,110018,castor oil,,,,,,
3163,"Fassi A, etal., Am J Kidney Dis. 1999 Feb;33(2):267-75. doi: 10.1016/s0272-6386(99)70299-4.",erythrocyte quantity,,RS:0000594,MWF,male,147 days to 133 days,6,,CMO:0000037,hematocrit,,,,49,%,0.4082,1.0,MMO:0000214,hematocrit analysis,,0.0,,,,,cyclosporine A (50 mg/kg/d) (for 7 days),110019,cyclosporine A (50 mg/kg/d) (for 7 days),,,,,,
3163,"Fassi A, etal., Am J Kidney Dis. 1999 Feb;33(2):267-75. doi: 10.1016/s0272-6386(99)70299-4.",erythrocyte quantity,,RS:0000594,MWF,male,147 days to 133 days,7,,CMO:0000037,hematocrit,,,,49,%,0.378,1.0,MMO:0000214,hematocrit analysis,,0.0,,,,,cyclosporine A (50 mg/kg/d) (for 7 days) and lacidipine (1 mg/kg/d) (for 7 days),110020,cyclosporine A (50 mg/kg/d) (for 7 days),lacidipine (1 mg/kg/d) (for 7 days),,,,,
3130,"Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19.",erythrocyte quantity,,RS:0000593,MWF/Hsd,male,84 days,5,,CMO:0000037,hematocrit,,,,44.2,%,0.3,0.6708,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,108785,control condition,,,,,,
3130,"Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19.",erythrocyte quantity,,RS:0004793,HsdCpb:WU,male,84 days,5,,CMO:0000037,hematocrit,,,,47.6,%,0.4,0.8944,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,108784,control condition,,,,,,
3130,"Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19.",erythrocyte quantity,,RS:0004793,HsdCpb:WU,male,175 days,10,,CMO:0000037,hematocrit,,,,47.8,%,0.6,1.8974,MMO:0000214,hematocrit analysis,,0.0,,,,,sham surgical control condition,108802,sham surgical control condition,,,,,,
3130,"Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19.",erythrocyte quantity,,RS:0004793,HsdCpb:WU,male,175 days,6,,CMO:0000037,hematocrit,,,,48.7,%,1.0,2.4495,MMO:0000214,hematocrit analysis,,0.0,,,,,left anterior descending coronary artery occlusion,108803,left anterior descending coronary artery occlusion,,,,,,
3130,"Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19.",erythrocyte quantity,,RS:0000593,MWF/Hsd,male,175 days,9,,CMO:0000037,hematocrit,,,,45,%,0.8,2.4,MMO:0000214,hematocrit analysis,,0.0,,,,,sham surgical control condition,108804,sham surgical control condition,,,,,,
3130,"Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19.",erythrocyte quantity,,RS:0000593,MWF/Hsd,male,175 days,10,,CMO:0000037,hematocrit,,,,45.7,%,0.7,2.2136,MMO:0000214,hematocrit analysis,,0.0,,,,,left anterior descending coronary artery occlusion,108805,left anterior descending coronary artery occlusion,,,,,,
3130,"Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19.",erythrocyte quantity,,RS:0004793,HsdCpb:WU,male,175 days,5,,CMO:0000037,hematocrit,,,,48.7,%,1.0,2.2361,MMO:0000214,hematocrit analysis,,0.0,,,,,left anterior descending coronary artery occlusion,108862,left anterior descending coronary artery occlusion,,,,,,
3130,"Szymanski MK, etal., Basic Res Cardiol. 2012 Mar;107(2):242. doi: 10.1007/s00395-011-0242-4. Epub 2012 Jan 19.",erythrocyte quantity,,RS:0000593,MWF/Hsd,male,175 days,9,,CMO:0000037,hematocrit,,,,45.7,%,0.7,2.1,MMO:0000214,hematocrit analysis,,0.0,,,,,left anterior descending coronary artery occlusion,108863,left anterior descending coronary artery occlusion,,,,,,
3169,"Ferrari P, etal., J Hypertens. 1987 Apr;5(2):199-206. doi: 10.1097/00004872-198704000-00011.",erythrocyte quantity,,RS:0000578,MHS/Gib,not specified,70 days to 50 days,6,,CMO:0000037,hematocrit,,,,46.4,%,0.7,1.7146,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,110327,control condition,,,,,,
3169,"Ferrari P, etal., J Hypertens. 1987 Apr;5(2):199-206. doi: 10.1097/00004872-198704000-00011.",erythrocyte quantity,,RS:0000581,MNS/Gib,not specified,70 days to 50 days,6,,CMO:0000037,hematocrit,,,,48,%,0.4,0.9798,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,110328,control condition,,,,,,
3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,56 days,20,,CMO:0000037,hematocrit,,,,47.6,%,0.0224,0.1,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) ,107810,DHD/K12/TRb cells (1.5 X 10E6) ,,,,,,
3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000037,hematocrit,,,,52.3,%,0.9487,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107811,DHD/K12/TRb cells (1.5 X 10E6) ,,vehicle control condition (1 ml) ,,,,
3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,71 days,10,,CMO:0000037,hematocrit,,,,52.7,%,0.6957,2.2,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) ,107812,DHD/K12/TRb cells (1.5 X 10E6) ,,sanguinarine (5 mg/kg/d) ,,,,
3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000037,hematocrit,,,,51,%,1.0436,3.3,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then vehicle control condition (1 ml) ,107813,DHD/K12/TRb cells (1.5 X 10E6) ,,vehicle control condition (1 ml) ,,,,
3097,"Pica F, etal., Anticancer Drugs. 2012 Jan;23(1):32-42. doi: 10.1097/CAD.0b013e32834a0c8e.",erythrocyte quantity,"red blood cell count, hematocrit",RS:0001789,BDIX/CrCrl,male,92 days,10,,CMO:0000037,hematocrit,,,,44,%,0.9803,3.1,MMO:0000214,hematocrit analysis,,0.0,,,,,DHD/K12/TRb cells (1.5 X 10E6) then sanguinarine (5 mg/kg/d) ,107814,DHD/K12/TRb cells (1.5 X 10E6) ,,sanguinarine (5 mg/kg/d) ,,,,
3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",erythrocyte size trait,,RS:0005133,Sah:SD,not specified,0 days,N/A,,CMO:0000038,mean corpuscular volume,,,,57.5,fl,0.5,,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,111444,control condition,,,,,,
3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",erythrocyte size trait,,RS:0005135,SD-Cftrem2Apb,not specified,0 days,N/A,,CMO:0000038,mean corpuscular volume,,,,63,fl,0.0,,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled ColonLYTELY content drinking water (4.5 %) ,111446,controlled ColonLYTELY content drinking water (4.5 %) ,,,,,,
3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",erythrocyte size trait,,RS:0005134,SD-Cftrem1Apb,not specified,0 days,N/A,,CMO:0000038,mean corpuscular volume,,,,59.33,fl,1.67,,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,111445,control condition,,,,,,
3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",erythrocyte quantity,,RS:0005134,SD-Cftrem1Apb,not specified,0 days,N/A,,CMO:0000037,hematocrit,,,,51,%,4.0,,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,111448,control condition,,,,,,
3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",erythrocyte quantity,,RS:0005135,SD-Cftrem2Apb,not specified,0 days,N/A,,CMO:0000037,hematocrit,,,,48,%,4.0,,MMO:0000214,hematocrit analysis,,0.0,,,,,controlled ColonLYTELY content drinking water (4.5 %) ,111449,controlled ColonLYTELY content drinking water (4.5 %) ,,,,,,
3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",erythrocyte quantity,,RS:0005133,Sah:SD,not specified,0 days,N/A,,CMO:0000037,hematocrit,,,,49,%,2.0,,MMO:0000214,hematocrit analysis,,0.0,,,,,control condition,111447,control condition,,,,,,